Filing Details
- Accession Number:
- 0001764013-24-000071
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-10 16:16:24
- Reporting Period:
- 2024-04-09
- Accepted Time:
- 2024-04-10 16:16:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1764013 | Immunovant Inc. | IMVT | Biological Products, (No Disgnostic Substances) (2836) | 832771572 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1796290 | G. Julia Butchko | C/O Immunovant, Inc. 320 W 37Th Street, 6Th Floor New York NY 10018 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-04-09 | 1,053 | $31.18 | 461,742 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on April 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 - $31.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.